What the NICE guidelines for Wegovy actually mean for patients

What NICE actually decided, and what TA875 does not guarantee

NICE's appraisal of semaglutide for weight management, TA875, was published in March 2023. It recommends Wegovy as a treatment option for adults who have a BMI of at least 35 and at least one weight-related health condition, things like type 2 diabetes, high blood pressure, or obstructive sleep apnoea. For people from South Asian, Chinese, Middle Eastern, Black African, or African-Caribbean backgrounds, the qualifying thresholds are 2.5 kg/m² lower throughout. A BMI of 30 to 34.9 can also qualify if the person meets the referral criteria for specialist weight management.

Crucially, TA875 ties access to a specialist multidisciplinary service. That is not the same as a routine GP visit. NHS England also specifies that Wegovy should be used for no longer than two years under this recommendation, a time limit that does not appear in the licensed criteria for private prescribing. So meeting the NICE thresholds on paper does not translate automatically into a prescription; it means you may be eligible to be referred, then assessed, then placed on a waiting list that in many areas runs to months or longer.

If you're wondering how Wegovy compares with tirzepatide under NICE's separate appraisal, the Wegovy vs Mounjaro comparison sets that out clearly, including the different eligibility thresholds each appraisal uses.

The real decision: NHS route or private prescribing?

Once you understand the NICE framework, the practical question becomes straightforward: do you meet the NHS criteria and are you willing to wait, or does private prescribing make more sense for you right now?

The NHS route follows TA875's eligibility conditions and the availability of a local specialist service. Some areas have waiting times of six months or more. Wraparound dietary and behavioural support is built into the NHS pathway, that is part of what the service provides, not an optional extra. If you do get access, your treatment is funded for up to two years and reviewed at the six-month mark: if you have not lost at least 5% of your starting weight on the maintenance dose by then, NICE says continuing should be reconsidered.

Private prescribing works from the Wegovy SmPC rather than TA875, so the eligibility criteria differ. A BMI of 30 or above qualifies, as does a BMI between 27 and 29.9 alongside a qualifying weight-related condition, assessed individually by a prescriber. There is no two-year cap written into the licence. The trade-off is cost. You can find a broader sense of what private treatment costs in the weight-loss treatment overview, which puts those figures in context.

The practical guide to finding a reputable Wegovy provider covers what to look for in a legitimate private service if you go that route.

How the 7.2mg approval changes the picture for 2025 and beyond

When most people think of Wegovy, they think of the 2.4mg weekly maintenance dose studied in the STEP 1 trial, which showed an average weight reduction of around 15% over 68 weeks, as published in the New England Journal of Medicine. That figure is still the baseline reference in TA875.

In April 2026, the MHRA approved a dedicated 7.2mg single-dose Wegovy pen. Trials at 7.2mg reported average weight loss of around 20.7% over 72 weeks, closer to tirzepatide's 15mg results. This higher dose is licensed for adults with a BMI of 30 or above only; it is not available for the 27-plus-comorbidity group, and it is not yet part of the NICE appraisal. NICE appraisals move on their own timetable and a formal update to TA875 would be required before the NHS could commission 7.2mg at scale.

For private patients, the licensed dose is already available subject to a prescriber's assessment, though specific dose availability is always confirmed at consultation rather than assumed. Timing matters here in a practical sense, if you've been putting off a consultation until after payday or a holiday, it's worth knowing that seeing an online doctor for Wegovy means access to newer dose options through private routes does not depend on waiting for NICE to catch up with the regulator.

You can read more about how different semaglutide products are licensed in the UK on the guide to Wegovy's names and formulations.

What NICE guidelines mean for your consultation

Whether you pursue the NHS or private route, a prescriber's assessment is the starting point. NICE guidelines shape what NHS commissioners fund; they do not replace clinical judgement, and they are not a checklist you self-certify. A prescriber will look at your full health picture: current weight, BMI, relevant conditions, any medicines you're already taking, and whether there are any reasons Wegovy may not be suitable for you.

Under the licence, Wegovy is not recommended during pregnancy, while breastfeeding, or when trying to conceive. It is not licensed for anyone under 18. People with a history of certain thyroid conditions, pancreatitis, or specific gastrointestinal diseases will need careful assessment. These exclusions apply regardless of whether you access treatment through the NHS or privately.

The age criteria for Wegovy are worth reading if you are near the boundaries of the licensed age range. And if you're uncertain whether semaglutide or another medicine is the better fit for your situation, the Wegovy comparison pages give a balanced, evidence-based overview. Our clinical team reviews every consultation personally, the same day it is submitted, by a GPhC-registered Independent Prescriber, not software. If you're ready to take the next step, you can start your free consultation and have your eligibility assessed today.